SGMT Sagimet Biosciences Inc.
USHealthcareAs of 2026-07-09 16:00
Why SGMT matters now
Sagimet Biosciences Inc. (SGMT) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.35 with -1.21% on the session and $239.5M in market capitalization; recent performance reads 1-month +2.14% and YTD +12.84%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.7M, and EPS of $-0.33. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.3%.
The latest indexable market news headline is "Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Phillips Anne M. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.12
P/S
0.00
EV/EBITDA
-3.92
DCF Value
$1.05
FCF Yield
-18.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-37.6%
ROA
-40.4%
ROIC
-47.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.7M | $-0.33 |
| Q4 2025 | $0.00 | $-9.6M | $-0.30 |
| FY 2025 | $0.00 | $-51.0M | $-1.58 |
| Q3 2025 | $0.00 | $-12.9M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.44
Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways. Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne. Additionally, Sagimet is advancing TVB-3567, another FASN inhibitor, which targets various forms of cancer. Founded in 2006, the company's main operations are located in San Mateo, California. It was formerly recognized as 3-V Biosciences, Inc. until it rebranded to Sagimet Biosciences Inc. in August 2019.